These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33951974)

  • 1. Tubing determination in an hematology oncology clinic.
    Hsin J; Mitchell J; Thompson J; Kaneshiro C; Troncoso A
    J Oncol Pharm Pract; 2021 Jul; 27(5):1186-1188. PubMed ID: 33951974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clinical pharmacy in oncology and hematology centers: A systematic review.
    Oliveira CS; Silva MP; Miranda ÍKSPB; Calumby RT; de Araújo-Calumby RF
    J Oncol Pharm Pract; 2021 Apr; 27(3):679-692. PubMed ID: 33302824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: Assessment and significance.
    Ali K; Al-Quteimat O; Naseem R; Malhi SM; Wajdi M; Jahan N; Ansari SH; Shamsi TS
    J Oncol Pharm Pract; 2021 Jun; 27(4):815-820. PubMed ID: 32633660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USP <800> and Strategies to Promote Hazardous Drug Safety.
    Eisenberg S
    J Infus Nurs; 2018; 41(1):12-23. PubMed ID: 29293194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Major therapeutic advances and new perspectives in onco-hematology].
    Bay JO; Guièze R; Ravinet A; Lemal R; Xhaard A; Bailly S; Moluçon-Chabrot C; Hermet E; Biau J; Verrelle P; Peffault de Latour R; Tournilhac O
    Bull Cancer; 2013 Jun; 100(6):587-99. PubMed ID: 23735575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing oncology nurses' use of hazardous drug safe-handling precautions.
    Polovich M; Clark PC
    Oncol Nurs Forum; 2012 May; 39(3):E299-309. PubMed ID: 22543401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidisciplinary care in the hematology clinic: Implementation of geriatric oncology.
    Goede V; Stauder R
    J Geriatr Oncol; 2019 May; 10(3):497-503. PubMed ID: 30241779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To cap or not to cap: chemotherapy dosing in obese adult hematology patients.
    Sandhu G; Mapp S; Carrington C; Hennig S
    Clin Pharmacol Ther; 2014 Apr; 95(4):356-8. PubMed ID: 24646484
    [No Abstract]   [Full Text] [Related]  

  • 9. Hematology/Oncology Clinics of North America. Hypercoagulable states and new anticoagulants. Preface.
    Crowther M; Donadini MP
    Hematol Oncol Clin North Am; 2010 Aug; 24(4):xiii-xiv. PubMed ID: 20659650
    [No Abstract]   [Full Text] [Related]  

  • 10. USP <800>: Gaining Compliance Through Implementation of a Hazardous Drug Control Program.
    Blake K
    Clin J Oncol Nurs; 2019 Jun; 23(3):324-326. PubMed ID: 31099798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.
    Haas M; Lonial S
    Expert Opin Investig Drugs; 2005 Sep; 14(9):1161-9. PubMed ID: 16144500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Geriatric Hematology Research presented at the 2018 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology Perspective Paper.
    Loh KP; Christofyllakis K; Huang LW; Mims A
    J Geriatr Oncol; 2019 Mar; 10(2):186-191. PubMed ID: 30661875
    [No Abstract]   [Full Text] [Related]  

  • 13. How to Develop and Maintain a Hazardous Drug List.
    Dillon LR
    Int J Pharm Compd; 2019; 23(3):182-186. PubMed ID: 31085785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The American Society of Hematology--46th Annual Meeting and Exposition. Drug highlights II.
    Evans L
    IDrugs; 2005 Jan; 8(1):10-3. PubMed ID: 15650933
    [No Abstract]   [Full Text] [Related]  

  • 15. Introduction to the Symposium on Neoplastic Hematology and Medical Oncology.
    Rajkumar SV; Kohli M
    Mayo Clin Proc; 2015 Jul; 90(7):848-9. PubMed ID: 26141326
    [No Abstract]   [Full Text] [Related]  

  • 16. [Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments].
    Jochims C; Mazitschek U; Jäger D; Goldschmidt H
    Internist (Berl); 2006 Jun; 47(6):633-41. PubMed ID: 16767478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study.
    Hadjibabaie M; Badri S; Ataei S; Moslehi AH; Karimzadeh I; Ghavamzadeh A
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1619-27. PubMed ID: 23589317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specialty pharmacy for hematologic malignancies.
    Fajardo S; Zook F; Dotson E
    Am J Health Syst Pharm; 2016 Jun; 73(11):797-809. PubMed ID: 27126835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended abstracts of the Annual Symposium of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR). June 12-14, 2008. Göttingen, Germany.
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):30-64. PubMed ID: 19385009
    [No Abstract]   [Full Text] [Related]  

  • 20. Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs.
    Dillon LR
    Int J Pharm Compd; 2020; 24(1):30-36. PubMed ID: 32023214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.